Analysis: Some said the vaccine rollout would be a ‘nightmare.’ They were right.
The country is just one week into the Covid-19 vaccine rollout, and it has become clear that America is ill-prepared for a mass vaccination campaign of this scale.
FDA revokes emergency use authorization for hydroxychloroquine in Covid-19
The agency said its own analysis of the EUA, issued in March, and emerging data showed the drug and a related compound, chloroquine, were unlikely to be effective. The Trump administration had aggressively promoted the drug despite a lack of supporting scientific evidence.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Trump’s hydroxychloroquine remarks drive renewed interest in drug as 96,000-patient analysis finds no Covid-19 benefit
The study, published in The Lancet, found a possible association between hydroxychloroquine and chloroquine and heart arrhythmias and death. Meanwhile, SingleCare saw a as much as a 22% increase in scripts filled for hydroxychloroquine following Trump's remarks last week.
Head of Trump’s Covid-19 vaccine program to divest more than $10M in Moderna shares after criticism
News media reported that Moncef Slaoui would divest his shares in Moderna, which netted him at least $3 million after the company reported promising preliminary data on its Covid-19 vaccine Monday.
Report: Trump organizes enterprise to shorten Covid-19 vaccine development by up to 8 months
Bloomberg reported Wednesday that the Trump administration is launching the effort, which it compared to the Manhattan Project, to shorten the length of time it would take to develop a vaccine for the disease.
Report: Trump sets sights on another unproven Covid-19 drug, this time from Fujifilm
Politico reported Tuesday that the Trump administration is trying to secure an emergency use authorization from the Food and Drug Administration for Fujifilm's Avigan. The FDA gave an EUA to two unproven antimalarial drugs over the weekend.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
FDA chief highlights Gilead drug’s availability under compassionate use for Covid-19
In remarks at the daily Coronavirus Task Force press briefing, FDA Commissioner Stephen Hahn pointed out that the drug, remdesivir, is available under compassionate use in addition to the ongoing clinical trials being run by Gilead Sciences and the NIH.
CureVac denies reports that Trump admin sought to acquire Covid-19 vaccine rights
German media reported Sunday that the administration had sought to lure its scientists to the U.S. Another company, Moderna, said Monday that it had dosed the first participant in its Phase I vaccine trial.
Trump’s proposed NIH cuts show disregard for importance of basic research
It's likely that many drugs Americans take for granted wouldn't exist today if not for the NIH-funded basic research that enabled their discovery and development. Fortunately, generous funding for the NIH has long enjoyed bipartisan support in Congress.
Trump officials look to ease privacy rules around addiction treatment records
Trump officials argue that current regulation has not kept up with the times and the necessity of coordinated approaches to addressing the opioid epidemic.
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Biotech execs criticize ‘atmosphere of intimidation’ amid actions against Chinese scientists
More than 150 people - including biotechnology and investment executives and academics - have signed a letter warning that actions dismissals of Chinese scientists create a hostile climate that threatens U.S. leadership in biomedical science.
CMS is bringing star quality ratings to health exchange plans
Rolling out the ratings nationwide is part of the Trump Administration's larger initiative to inject cost and quality transparency into the healthcare system.
Trump adviser described as ‘key architect’ of drug-pricing blueprint to step down
John O'Brien, a former insurance industry executive, will step down less than one year after his appointment as senior advisory to HHS Secretary Alex Azar on drug-pricing reform. He had worked for HHS since March 2017 and also previously worked for CMS.
New IRS rule opens up preventive care coverage for chronic disease by high-deductible health plans
Applicable products and services include insulin, ACE inhibitors, inhaled corticosteroids, retinopathy screenings, glucometers, statins and SSRIs.
Trump’s drug pricing blueprint hits a speed bump
The administration's plan to lower drug costs met two major setbacks last week. Experts weighed in on what that could mean.